重视生物制剂临床应用中的感染并发症  

Pay attention to the infectious complications in the clinical application of biological agents

作　　者：马小军[1] 刘曦[2] 葛瑛[1] Ma Xiaojun;Liu Xi;Ge Ying(Department of Infectious Disease,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Infectious Diseases,the Fifth Affiliated Hospital,Sun Yat-sen University,Zhuhai 519000,China)

机构地区：[1]中国医学科学院北京协和医院感染内科,北京100730 [2]中山大学附属第五医院感染病防治中心,珠海519000

出　　处：《中华医学杂志》2023年第33期2546-2551,共6页National Medical Journal of China

基　　金：北京协和医院中央高水平医院临研专项(2022-PUMCH-B-043)

摘　　要：生物制剂通过靶向特定的免疫细胞或细胞因子产生作用,已广泛应用于临床多种疾病的治疗;生物制剂在临床应用的过程中可导致继发性免疫缺陷,进而增加感染的风险。各种生物制剂引发的感染有何差异,如何早期识别不同的生物制剂治疗过程中的感染并发症,如何采取有效的、针对性的预防,目前尚无相关的循证指南或管理意见。本文总结了生物制剂在临床应用过程中需重点关注的感染并发症及其特征,旨在帮助临床医生在使用生物制剂的过程中,针对感染并发症做出合理决策,降低感染的发生率,提升诊疗成功率。Biological agents have been widely used in the treatment of many clinical diseases by targeting specific immune cells or cytokines.In the course of clinical use,biological agents can lead to secondary immune deficiency,which increases the risk of infection.At present,there are no evidence-based guidelines or management opinions on the differences of infections caused by various biological agents,how to identify infectious complications in the course of treatment with different biological agents at an early stage,and how to take effective and targeted prevention.This paper summarizes the infection complications and their characteristics that need to be paid attention to in the clinical introduction of biological agents,aiming to help clinicians make reasonable decisions for infection complications in the process of using biological agents,reduce the incidence of infection,and improve the success rate of diagnosis and treatment.

关 键 词：感染 生物制剂 靶向治疗 免疫抑制 免疫缺陷 

分 类 号：R979.5[医药卫生—药品]